BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ...
MUMBAI, India and LA CHAUX DE FONDS, Switzerland and BOSTON and SHANGHAI, Aug. 6, 2018 /PRNewswire/ -- Glenmark Pharmaceuticals S.A. and Harbour BioMed announced today that they have entered into an ...
(RTTNews) - Orchestra BioMed Holdings, Inc. (OBIO) said Tuesday it has signed a new right of first refusal (ROFR) agreement with Terumo Corporation and Terumo Medical Corporation that grants Terumo ...
VANCOUVER, British Columbia and NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a GMP-approved, Health Canada licensed psychedelics ...
The new project in collaboration with AbbVie aims to unravel the mechanisms of anhedonia and to identify novel therapeutic targets at the BioMed X Institute in New Haven. The topic of the new research ...
ROTTERDAM, The Netherlands & CAMBRIDGE, Mass. & SHANGHAI--(BUSINESS WIRE)--Harbour BioMed (HBM) and Erasmus MC, University Medical Center Rotterdam announced today that they have signed a 10-year ...
Exclusive license agreement potentially worth more than $120 million in addition to royalties GBR 1302 is a clinical stage, HER2xCD3 bispecific antibody generated from Glenmark’s proprietary BEAT™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback